O	0	6	Effect
O	7	9	of
B-intervention	10	19	melatonin
O	20	22	on
B-condition	23	33	depressive
I-condition	34	42	symptoms
I-condition	43	46	and
I-condition	47	54	anxiety
O	55	57	in
O	58	66	patients
O	67	77	undergoing
O	78	84	breast
O	85	91	cancer
O	92	99	surgery
O	99	100	:
O	101	102	a
O	103	113	randomized
O	113	114	,
O	115	121	double
O	121	122	-
O	122	127	blind
O	127	128	,
O	129	136	placebo
O	136	137	-
O	137	147	controlled
O	148	153	trial
O	153	154	.

O	155	165	Depression
O	165	166	,
O	167	174	anxiety
O	175	178	and
O	179	184	sleep
O	185	197	disturbances
O	198	201	are
O	202	207	known
O	208	216	problems
O	217	219	in
O	220	228	patients
O	229	233	with
O	234	240	breast
O	241	247	cancer
O	247	248	.

O	249	252	The
O	253	259	effect
O	260	262	of
O	263	272	melatonin
O	273	275	as
O	276	278	an
O	279	293	antidepressant
O	294	296	in
O	297	303	humans
O	304	308	with
O	309	315	cancer
O	316	319	has
O	320	323	not
O	324	328	been
O	329	341	investigated
O	341	342	.

O	343	345	We
O	346	358	investigated
O	359	366	whether
O	367	376	melatonin
O	377	382	could
O	383	388	lower
O	389	392	the
O	393	397	risk
O	398	400	of
O	401	411	depressive
O	412	420	symptoms
O	421	423	in
B-eligibility	424	429	women
I-eligibility	430	434	with
I-eligibility	435	441	breast
I-eligibility	442	448	cancer
O	449	451	in
O	452	453	a
O	454	459	three
O	459	460	-
O	460	465	month
O	466	472	period
O	473	478	after
O	479	486	surgery
O	487	490	and
O	491	499	assessed
O	500	503	the
O	504	510	effect
O	511	513	of
O	514	523	melatonin
O	524	526	on
O	527	537	subjective
O	538	548	parameters
O	548	549	:
O	550	557	anxiety
O	557	558	,
O	559	564	sleep
O	564	565	,
O	566	573	general
O	574	578	well
O	578	579	-
O	579	584	being
O	584	585	,
O	586	593	fatigue
O	593	594	,
O	595	599	pain
O	600	603	and
O	604	614	sleepiness
O	614	615	.

O	616	626	Randomized
O	626	627	,
O	628	634	double
O	634	635	-
O	635	640	blind
O	640	641	,
O	642	649	placebo
O	649	650	-
O	650	660	controlled
O	661	666	trial
O	667	677	undertaken
O	678	682	from
O	683	687	July
O	688	692	2011
O	693	695	to
O	696	704	December
O	705	709	2012
O	710	712	at
O	713	714	a
O	715	725	department
O	726	728	of
O	729	735	breast
O	736	743	surgery
O	744	746	in
B-location	747	757	Copenhagen
I-location	757	758	,
I-location	759	766	Denmark
O	766	767	.

O	768	773	Women
O	773	774	,
B-age	775	777	30
I-age	777	778	-
I-age	778	780	75
I-age	781	786	years
O	786	787	,
O	788	798	undergoing
O	799	806	surgery
O	807	810	for
O	811	817	breast
O	818	824	cancer
O	825	828	and
O	829	836	without
O	837	842	signs
O	843	845	of
O	846	856	depression
O	857	859	on
O	860	865	Major
O	866	876	Depression
O	877	886	Inventory
O	887	888	(
O	888	891	MDI
O	891	892	)
O	893	897	were
O	898	906	included
O	907	908	1
O	909	913	week
O	914	920	before
O	921	928	surgery
O	929	932	and
O	933	941	received
O	942	943	6
O	944	946	mg
O	947	951	oral
O	952	961	melatonin
O	962	964	or
B-control	965	972	placebo
O	973	976	for
O	977	978	3
O	979	985	months
O	985	986	.

O	987	990	The
O	991	998	primary
O	999	1006	outcome
O	1007	1010	was
O	1011	1014	the
B-outcome-Measure	1015	1024	incidence
I-outcome-Measure	1025	1027	of
I-outcome-Measure	1028	1038	depressive
I-outcome-Measure	1039	1047	symptoms
O	1048	1056	measured
O	1057	1059	by
O	1060	1063	MDI
O	1063	1064	.

O	1065	1068	The
O	1069	1078	secondary
O	1079	1087	outcomes
O	1088	1092	were
B-outcome-Measure	1093	1097	area
I-outcome-Measure	1098	1103	under
I-outcome-Measure	1104	1107	the
I-outcome-Measure	1108	1113	curve
I-outcome-Measure	1114	1115	(
I-outcome-Measure	1115	1118	AUC
I-outcome-Measure	1118	1119	)
I-outcome-Measure	1120	1123	for
I-outcome-Measure	1124	1127	the
I-outcome-Measure	1128	1138	subjective
I-outcome-Measure	1139	1149	parameters
O	1149	1150	.

B-total-participants	1151	1153	54
O	1154	1162	patients
O	1163	1167	were
O	1168	1178	randomized
O	1179	1181	to
O	1182	1191	melatonin
O	1192	1193	(
O	1193	1194	n
O	1195	1196	=
B-intervention-participants	1197	1199	28
O	1199	1200	)
O	1201	1203	or
O	1204	1211	placebo
O	1212	1213	(
O	1213	1214	n
O	1215	1216	=
B-control-participants	1217	1219	26
O	1219	1220	)
O	1221	1224	and
O	1225	1227	11
O	1228	1236	withdrew
O	1237	1241	from
O	1242	1245	the
O	1246	1251	study
O	1252	1253	(
O	1253	1255	10
O	1256	1263	placebo
O	1264	1269	group
O	1270	1273	and
O	1274	1275	1
O	1276	1285	melatonin
O	1286	1291	group
O	1291	1292	,
O	1293	1294	P
O	1295	1296	=
O	1297	1298	0
O	1298	1299	.
O	1299	1302	002
O	1302	1303	)
O	1303	1304	.

O	1305	1308	The
B-outcome	1309	1313	risk
I-outcome	1314	1316	of
I-outcome	1317	1327	developing
I-outcome	1328	1338	depressive
I-outcome	1339	1347	symptoms
O	1348	1351	was
O	1352	1365	significantly
O	1366	1371	lower
O	1372	1376	with
O	1377	1386	melatonin
O	1387	1391	than
O	1392	1396	with
O	1397	1404	placebo
O	1405	1406	(
B-iv-bin-abs	1406	1407	3
O	1408	1409	[
B-iv-bin-percent	1409	1411	11
I-iv-bin-percent	1412	1413	%
O	1413	1414	]
O	1415	1417	of
B-intervention-participants	1418	1420	27
O	1421	1423	vs
O	1423	1424	.
B-cv-bin-abs	1425	1426	9
O	1427	1428	[
B-cv-bin-percent	1428	1430	45
I-cv-bin-percent	1431	1432	%
O	1432	1433	]
O	1434	1436	of
B-control-participants	1437	1439	20
O	1439	1440	;
O	1441	1449	relative
O	1450	1454	risk
O	1455	1456	0
O	1456	1457	.
O	1457	1459	25
O	1460	1461	[
O	1461	1463	95
O	1464	1465	%
O	1466	1468	CI
O	1469	1470	0
O	1470	1471	.
O	1471	1474	077
O	1474	1475	-
O	1475	1476	0
O	1476	1477	.
O	1477	1479	80
O	1479	1480	]
O	1480	1481	)
O	1481	1482	,
O	1483	1489	giving
O	1490	1491	a
O	1492	1495	NNT
O	1496	1498	of
O	1499	1500	3
O	1500	1501	.
O	1501	1502	0
O	1503	1504	[
O	1504	1506	95
O	1507	1508	%
O	1509	1511	CI
O	1512	1513	1
O	1513	1514	.
O	1514	1515	7
O	1515	1516	-
O	1516	1518	11
O	1518	1519	.
O	1519	1520	0
O	1520	1521	]
O	1521	1522	.

O	1523	1525	No
O	1526	1537	significant
O	1538	1549	differences
O	1550	1554	were
O	1555	1560	found
O	1561	1568	between
O	1569	1572	AUC
O	1573	1576	for
O	1577	1580	the
O	1581	1591	subjective
O	1592	1602	parameters
O	1602	1603	.

O	1604	1606	No
O	1607	1618	differences
O	1619	1621	in
O	1622	1626	side
O	1627	1634	effects
O	1635	1639	were
O	1640	1645	found
O	1646	1647	(
O	1647	1648	P
O	1649	1650	=
O	1651	1652	0
O	1652	1653	.
O	1653	1655	78
O	1655	1656	)
O	1656	1657	.

O	1658	1667	Melatonin
O	1668	1681	significantly
O	1682	1689	reduced
O	1690	1693	the
O	1694	1698	risk
O	1699	1701	of
O	1702	1712	depressive
O	1713	1721	symptoms
O	1722	1724	in
O	1725	1730	women
O	1731	1735	with
O	1736	1742	breast
O	1743	1749	cancer
O	1750	1756	during
O	1757	1758	a
O	1759	1764	three
O	1764	1765	-
O	1765	1770	month
O	1771	1777	period
O	1778	1783	after
O	1784	1791	surgery
O	1791	1792	.
